Skip to main content

Table 2 Laboratory parameters in moderately, severely and critically ill COVID-19 patients

From: An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Baseline parameters Moderately ill Patients Severely ill patients Critically ill patients All patients p value
(n = 11) (n = 7) (n = 6)
Hemoglobin (g/l) 112.4 ± 16.63 104 ± 22.35 90.17 ± 37.73 102.6 ± 27.26 0.744 ANOVA
White blood cell (× 109/L) 6.925 ± 2.842 7.92 ± 2.366 11.08 ± 4.304 8.5 ± 3.599 0.090
K-W
Neutrophil (× 109/L) 4.462 ± 2.055 4.777 ± 3.417 9.537 ± 4.154 5.882 ± 3.712 0.012 ANOVA
Lymphocyte (× 109/L) 1.571 ± 0.6184 1.634 ± 0.689 1.059 ± 0.5516 1.44 ± 0.6363 0.227 ANOVA
NLR 3.825 ± 3.317 6.389 ± 9.717 10.82 ± 6.083 6.433 ± 6.501 0.065
K-W
Platelet (× 109/L) 198.5 ± 41.79 231.2 ± 32.69 311 ± 156.9 224 ± 88.83 0.413 ANOVA
PLR 171.8 ± 154.5 243.2 ± 251.9 226.9 ± 223.4 227.8 ± 195.8 0.208
K-W
Triglycerides (mmol/L) 1.023 ± 0.2329 1.197 ± 0.2871 1.962 ± 1.081 1.408 ± 0.7893 0.080 ANOVA
ALT (U/L) 18.86 ± 13.63 18 ± 15.75 36.67 ± 22.54 24.94 ± 18.84 0.168 ANOVA
D-Dimer (mg/l) 0.92 ± 0.6479 2.07 ± 1.669 1.773 ± 0.7467 1.396 ± 0.924 0.744 ANOVA
  1. Abbreviations: NLR Neutrophil-to-lymphocyte ratio; PLR Platelet-to-lymphocyte ratio; ALT Alanine aminotransferase; ANOVA Analysis of variance; K-W Kruskall-Wallis